바이오앱

비상장계속사업자

BioaApplications Inc.

손은주

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

바이오앱

Business Reg. No. 5068176875 · CEO 손은주

I.Investment Overview

Target바이오앱 (5068176875)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명바이오앱
영문명BioaApplications Inc.
대표자손은주
사업자등록번호5068176875
법인등록번호1717110095230
설립일2011.08.16
종업원수35명

V.Workforce

35

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW4.4202112.9202213.9202315.6202420.62025
영업이익100M KRW-53.52021-54.52022-59.22023-40.82024-29.82025
순이익100M KRW-2292021-63.62022167.62023-142024-60.32025
Item20252024202320222021
자산총계81.3억원78.3억원106.3억원153.2억원147.2억원
부채총계32.3억원220.5억원234.6억원449.4억원432.3억원
자본총계48.9억원-142.1억원-128.4억원-296.2억원-285.1억원
매출액20.6억원15.6억원13.9억원12.9억원4.4억원
영업이익-29.8억원-40.8억원-59.2억원-54.5억원-53.5억원
순이익-60.3억원-14억원167.6억원-63.6억원-229억원

VII.Financial Ratios

FY2025 basis

-145.14%

영업이익률

-293.54%

순이익률

-74.24%

ROA

-123.28%

ROE

66.06%

부채비율

60.22%

자기자본비율

VIII.R&D Activity

Fields 보건의료 > 신약·의약품개발 · 농림수산식품 > 수의과학 · 생명과학 > 기타 생명과학

Keywords 돼지열병, 백신, 마커백신, 돼지생식기호흡기증후군, 제품화

YearProjectsPapersPatents
2026400
2025420
2024210
2023216
2022404
2021615
2020213
2019314
2018118
2017302
2016214
2015211
2014111
2013200
2012101

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

바이오앱 투심보고서 | Alpha Lenz